SCHEMBL6713729

SCHEMBL6713729

COc1ccc(-c2ccc3c(c2)cc2n3CCNCC2)c(CO)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.54
HTR2C P28335 5/20 0.54
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
HTR1A P08908 2/20 0.37
HTR7 P34969 1/20 0.37
BAZ2B Q9UIF8 1/20 0.36
BAZ2A Q9UIF9 1/20 0.36
SYK P43405 2/20 0.36
AURKB Q96GD4 2/20 0.36
INCENP Q9NQS7 2/20 0.36
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
ADRB1 P08588 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
MLNR O43193 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6719010 0.92 HTR2A (0.54) HTR2AHTR2CCYP11B1CYP11B2HTR1A
SCHEMBL6711423 0.91 HTR2A (0.55) HTR2AHTR2CHTR1AHTR7SYK
SCHEMBL6711194 0.90 HTR2A (0.54) HTR2AHTR2CCYP11B1CYP11B2HTR1A
SCHEMBL6714091 0.88 HTR2A (0.52) HTR2AHTR2CHTR1AHTR7SYK
SCHEMBL6715381 0.86 HTR2A (0.47) HTR2AHTR2CCYP11B1CYP11B2SYK
SCHEMBL6716207 0.85 HTR2A (0.58) HTR2AHTR2CCYP11B1CYP11B2HTR1A
SCHEMBL6718656 0.85 HTR2A (0.58) HTR2AHTR2CHTR1AHTR7SYK
SCHEMBL6712409 0.84 HTR2A (0.57) HTR2AHTR2CHTR1AHTR7SYK
SCHEMBL6713595 0.84 HTR2A (0.57) HTR2AHTR2CHTR1AHTR7SYK
SCHEMBL6713779 0.84 HTR2A (0.52) HTR2AHTR2CCYP11B1CYP11B2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885CYP11B1 188/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885CYP11B1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.